Bharat Biotech on Thursday said the company and Ocugen Inc, its US partner for COVID-19 vaccine Covaxin, have agreed to expand their agreement to commercialise the jab in Canada also.
Bharat Biotech on February 2 said it and Ocugen Inc a US-based biopharmaceutical companyhave entered into a definitive agreement to co-develop, supply, and commercialise, the India vaccine makers Covaxin for the USA market.
Ocugen, which is working towards the submission of the emergency use application in the US, will simultaneously seek authorisation under interim order for emergency use in Canada Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen said in a press release.
"This amendment to expand our rights to commercialize Covaxin into Canada speaks of our strong relationship with Bharat Biotech and our joint dedication to bring this unique yet traditional vaccine to additional countries," Musunuri said.
As the consideration for Bharat Biotechs grant of the rights to commercialise Covaxin in Canada, Ocugen will make an upfront payment and milestone payment upon first commercial sale in Canada to the Indian vaccine maker, in addition to sharing the profit from sales of the vaccine in that country.
Similar to the US profit share arrangement, Ocugen will retain 45 per cent of the profits from sales of Covaxin in Canada, the release said.
Krishna Ella, Chairman & Managing Director of Bharat Biotech said Covaxin has demonstrated an excellent safety record in human clinical trials and in vaccine administration under emergency use in India.
"We are diligently working with Ocugen to bring Covaxin to the US market and now to the Canadian market," Ella said.
With its potential effectiveness against multiple existing and emerging variants, Bharat Biotech believes that Covaxin is an important vaccine for everyone, including children, based on its unique yet traditional vaccine platform, he further said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU